Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure

Hofer, Felix; Kazem, Niema; Richter, Bernhard; Sulzgruber, Patrick; Schweitzer, Ronny; Pailer, Ulrike; Hammer, Andreas; Koller, Lorenz; Hengstenberg, Christian; Niessner, Alexander

doi:10.1007/s10557-021-07234-7

Cited by 9 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fortunately, the prescription rate has increased over time in this cohort. This finding is similar to a study by Hofer et al [27]. The increased rate of SGLT2i prescription in our cohort parallels the strong recommendations to use this class of medications in patients with diabetes with or without cardiovascular risk factors due to their favorable outcomes in risk reduction [20,24,28].…”

Section: Discussionsupporting

confidence: 92%

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia

Somaili¹,

Oraibi²,

Mohrag³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background: Sodium-glucose cotransporter inhibitors are promising medications for improving cardiovascular outcomes in diabetic and non-diabetic patients. The baseline characteristics associated with its prescription in Jazan, Saudi Arabia, are still lacking.Objectives: This study aims to determine the baseline characteristics associated with its prescription among type 2 diabetic patients in the Jazan region.Methods: A retrospective cohort study of adult patients with type 2 diabetes mellitus (T2DM) in Jazan region, Saudi Arabia, who received a prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) from June 2016 to December 2021 was conducted. Categorical baseline characteristics are reported as frequencies, and proportion and continuous variables are reported as means (SD). The crude odds and adjusted ratio (OR) (95% CI) for SGLT2i prescription were then calculated using univariate and multivariate logistic regression analysis.Results: A total of 370 patients who satisfied the inclusion criteria were included in this study. There were 133 patients (36%) who had been prescribed SGLT2i over a median follow-up of five years. Characteristics associated with the prescription were female gender (adjusted odds ratio [aOR]: 2.2, 95% Cl: 1.3-3.9), endocrinologist doctors (aOR: 2.4, 95% Cl: 1.3-4.5), patients who had visited the center four times or more

show abstract

Section: Discussionsupporting

confidence: 92%

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia

Somaili¹,

Oraibi²,

Mohrag³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…As seen in the EMPEROR-Preserved trial, a significant mortality benefit along with a reduced risk of re-hospitalization was observed, making the SGLT2i class of medications crucial for HFpEF patients in which treatment options remain limited [14] . While there has been an increase in prescription rates of SGLT2i over the past several years, the class still remains underutilized in daily clinical practice in both HFpEF and HFrEF populations [15] . According to our research, SGLT2i are especially underemployed in the HFpEF population as the prescription rate of SGLT2 inhibitors was significantly higher for the HFrEF population compared to the HFpEF population.…”

Section: Discussionmentioning

confidence: 99%

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis

Chakrala¹,

Prakash²,

Kim³

et al. 2023

American Heart Journal Plus: Cardiology Research and Practice

View full text Add to dashboard Cite

“…In the present work, advanced HF was defined based on recent guidelines [ 1 ]. Lastly, only 16.7% of patients were on SGLT-2 inhibitors at admission, mirroring the currently low global prescription rate of this drug category in HF populations [ 45 , 46 , 47 ].…”

Section: Study Limitationsmentioning

confidence: 99%

The Prognostic Role of Spot Urinary Sodium and Chloride in a Cohort of Hospitalized Advanced Heart Failure Patients: A Pilot Study

Xanthopoulos

Christofidis

Pantsios

et al. 2023

Life

View full text Add to dashboard Cite

Recent studies have demonstrated the prognostic value of spot urinary sodium (UNa+) in acutely decompensated chronic HF (ADCHF) patients. However, data on the prognostic role of UNa+ and spot urinary chloride (UCl−) in patients with advanced HF are limited. In the present prospective pilot study, we examined the predictive value of UNa+ and UCl− concentration at baseline, at 2 h and at 24 h after admission for all-cause mortality and HF rehospitalization up to 3 months post-discharge. Consecutive advanced HF patients (n = 30) admitted with ADCHF and aged > 18 years were included in the study. Loop diuretics were administered based on the natriuresis-guided algorithm recommended by the recent HF guidelines. Exclusion criteria were cardiogenic shock, acute coronary syndrome, estimated glomerular filtration rate < 15 mL/min/1.73 m2, severe hepatic dysfunction (Child–Pugh category C), and sepsis. UNa+ at baseline (Area Under the Curve (AUC) = 0.75, 95% Confidence Interval (CI) (0.58–0.93), p = 0.019) and at 2 h after admission (AUC = 0.80, 95% CI: 0.64–0.96, p = 0.005) showed good and excellent discrimination, respectively. UCl− at 2 h after admission (AUC = 0.75, 95%CI (0.57–0.93), p = 0.017) demonstrated good discrimination. In the multivariate logistic regression analysis, UNa+ at 2 h (p = 0.02) and dose of loop diuretics at admission (p = 0.03) were the only factors independently associated with the study outcome. In conclusion, UNa+ and UCl− may have a prognostic role in hospitalized advanced HF patients.

show abstract

Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure

Cited by 9 publications

References 17 publications

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia

Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis

The Prognostic Role of Spot Urinary Sodium and Chloride in a Cohort of Hospitalized Advanced Heart Failure Patients: A Pilot Study

Contact Info

Product

Resources

About